Letter to the editor. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

Best, O.G., Gardiner, A.C., Davis, Z.A., Tracy, I., Ibbotson, R.E., Majid, A., Dyer, M.J.S. and Oscier, D.G. (2009) Letter to the editor. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia, 23 (1), 212-214. (doi:10.1038/leu.2008.260).

Abstract

TP53 abnormalities consistently emerge as the most significant adverse prognostic factor in multivariate analyses of both prospective and retrospective studies in early and advanced chronic lymphocytic leukaemia (CLL).1 In view of the higher response rates often achieved with alemtuzumab-containing regimens compared with alkylating agent and/or purine analogue therapy2 and the possibility of long-term disease-free survival following allogeneic transplantation in some patients, there is an increasing consensus for screening for TP53 abnormalities in CLL patients who fulfil the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) recommendations for initiating therapy.

This record has no associated files available for download.

Contributors

Download statistics